P3-090: Disease stabilization (SD) as a surrogate end-point in advanced non-small-cell lung cancer (NSCLC) patients treated with erlotinib (E) or gefitinib (G)

  • Francesco Grossi, Carlotta Defferrari, Annalisa Brianti, Gianluca Catania, Maura Loprevite, Maria Giovanna Dal Bello, Paolo Pronzato
  • Journal of Thoracic Oncology, August 2007, Elsevier
  • DOI: 10.1097/01.jto.0000284066.68354.15

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication


The following have contributed to this page: Dr Gianluca Catania